European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease

Authors

  • Costas G. Alexopoulos
  • StΓ©phane Alard
  • Thierry Berghmans
  • Marie-Claude Berchier
  • Yves Bonduelle
  • Benoit Colinet
  • Thierry Collon
  • Sophie Desurmont
  • Anna Efremidis
  • Xavier Ficheroulle
  • Marie-Chantal Florin
  • Vicente Giner
  • StΓ©phane Holbrecht
  • George Koumakis
  • Jean-Jacques Lafitte
  • Nathalie Leclercq
  • Ingrid Louviaux
  • Eveline Markiewicz
  • CΓ©line Mascaux
  • Anne-Pascale Meert
  • Marianne Paesmans
  • Pol Ravez
  • Michel Richez
  • Martine Roelandts
  • Jean-Paul Sculier
  • Christian Tulippe
  • Oswald Van Cutsem
  • Paul Van Houtte
  • Michael M. Vaslamatzis
  • Patricia Wackenier

DOI:

https://doi.org/10.2015/hc.v1i3.20

Keywords:

guidelines, non-small cell lung cancer, advanced stages, chemotherapy, platinum-based regimen, carboplatin, targeted therapy

Abstract

The present guidelines on the management of advanced non-small cell lung cancer (NS CLC) were formulated by the ELCWP in October 2006. They are designed to answer the following twelve questions: 1) What benefits can be expected from chemotherapy and what are the treatment objectives? 2) What are the active chemotherapeutic drugs for which efficacy has been shown? 3) Which are the most effective platinum-based regimens? 4) Which is the indicated dosage of cisplatin? 5) Can carboplatin be substituted for cisplatin? 6) Which is the optimal number of cycles to be administered? 7) Can non-platinum based regimens be substituted for platinum based chemotherapy as first-line treatment? 8) Is there an indication for sequential chemotherapy? 9) What is the efficacy of salvage chemotherapy and which drugs should be used in that indication? 10) What is the place of targeted therapies? 11) What is the place of chemotherapy in the management of a patient with brain metastases? 12) Which specific drugs can be used for the patient with bone metastases?

Downloads

Issue

Vol. 1 No. 3 (2006)

Section

Special Topic

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).